This site uses cookies to deliver our services and to show you relevant ads and presentations. By clicking on "Accept", you acknowledge that you have read and understand our Cookie Policy , Privacy Policy , and our Terms of Use.
X

Download Effect of RHDL on Atherosclerosis-Safety PowerPoint Presentation


Login   OR  Register
X


Iframe embed code :



Presentation url :

X

Description :

Available Effect of RHDL on Atherosclerosis-Safety powerpoint presentation for free download which is uploaded by search an active user in belonging ppt presentation Health & Wellness category.

Tags :

Effect of RHDL on Atherosclerosis-Safety

Home / Health & Wellness / Health & Wellness Presentations / Effect of RHDL on Atherosclerosis-Safety PowerPoint Presentation

Effect of RHDL on Atherosclerosis-Safety PowerPoint Presentation

Ppt Presentation Embed Code   Zoom Ppt Presentation

About This Presentation


Description : Available Effect of RHDL on Atherosclerosis-Safety powerpoint presentation for free download which i... Read More

Tags : Effect of RHDL on Atherosclerosis-Safety

Published on : Mar 14, 2014
Views : 472 | Downloads : 0


Download Now

Share on Social Media

             

PowerPoint is the world's most popular presentation software which can let you create professional Effect of RHDL on Atherosclerosis-Safety powerpoint presentation easily and in no time. This helps you give your presentation on Effect of RHDL on Atherosclerosis-Safety in a conference, a school lecture, a business proposal, in a webinar and business and professional representations.

The uploader spent his/her valuable time to create this Effect of RHDL on Atherosclerosis-Safety powerpoint presentation slides, to share his/her useful content with the world. This ppt presentation uploaded by onlinesearch in this Health & Wellness category is available for free download,and can be used according to your industries like finance, marketing, education, health and many more.

SlidesFinder.com provides a platform to marketers, presenters and educationists along with being the preferred search engine for professional PowerPoint presentations on the Internet to upload their Effect of RHDL on Atherosclerosis-Safety ppt presentation slides to help them BUILD THEIR CROWD!!

User Presentation
Related Presentation
Free PowerPoint Templates
Slide 1 - The ERASE Trial: Effect of rHDL on Atherosclerosis-Safety and Efficacy Presented at American College of Cardiology Annual Scientific Session 2007 Presented by Dr. Jean-Claude Tardif, M.D. ERASE Trial
Slide 2 - ERASE Trial: Background CSL-111 is an apolipoprotein A-I isolated from human plasma and phosphatidylcholine derived from soybean. Commercial development of the cholesteryl ester transfer protein inhibitor torcetrapib was recently stopped after a trial showed an increase in mortality with torcetrapib. ACC 2007
Slide 3 - ERASE Trial: Background CSL-111 is a different class of agents targeting increasing HDL and is not a CETP inhibitor but is derived from human plasma. The goal of this trial was to evaluate the effect of plaque burden of reconstituted HDL compared with placebo among patients with recent acute coronary syndromes. ACC 2007
Slide 4 - CSL-111 40 mg/kg n=111 ERASE Trial: Study Design CSL-111 80 mg/kg n=12 Placebo Matching Dose n=60 183 patients aged 30-75 years with clinical need for coronary angiography, defined as ≥ 1 narrowing ≥20% coronary angiography at baseline; within 2 weeks of having an acute coronary syndrome defined as unstable angina or non-ST-segment or ST-segment elevation MI Placebo-controlled. Randomized. Double-blinded. Mean follow-up: 6 weeks. 17% female. ACC 2007 Primary Endpoint: Percentage change in atheroma volume from baseline to 6 weeks Secondary Endpoint: Absolute change in plaque volume, change in plaque characterization indexes on IVUS, and change in coronary score on quantitative coronary angiography. 80 mg group discontinued 6 week follow-up R
Slide 5 - ERASE Trial: Primary Endpoint Percent Change in Atheroma Volume from Baseline to 6 weeks The primary endpoint of percent change in atheroma volume from baseline to 6 weeks did not differ between treatment groups (-3.4% in the CSL-111 group vs. -1.6% in the placebo group, p=0.48) Placebo CSL-111 Change in atheroma volume (%) ACC 2007 p = 0.48
Slide 6 - ERASE Trial: Secondary Endpoint Absolute Change in Atheroma Volume from Basleine to 6 weeks The absolute change in atheroma volume from baseline to 6 weeks also did not differ between treatment groups (-5.3mm3 in the CSL-111 group vs. -2.3 mm3 in the placebo group, p=0.39) Placebo CSL-111 Absolute change in atheroma volume (mm3) ACC 2007 p = 0.39
Slide 7 - ERASE Trial: Secondary Endpoints Mean change in plaque characterization index on IVUS was -0.0097 for CSL-111 and +0.0128 for placebo (p=0.01). Reduction in coronary score on angiography was significantly less with CSL-111 compared with placebo (-0.039 mm for CSL-111 vs. -0.071 mm for placebo, p=0.03). ACC 2007
Slide 8 - ERASE Trial: Limitations The 80 mg CSL-111 group was discontinued due to high rates of abnormal liver function tests, including alanine aminotransferase >5 times the upper limit of normal (ULN) in 50% of the group and aspartate aminotransferase >5 times ULN in 33% of the group. The lipid effects of the agent in the study were not reported. A larger trial would be required to evaluate the clinical safety and efficacy of this agent. ACC 2007
Slide 9 - ERASE Trial: Summary Among patients with recent acute coronary syndromes, treatment with the novel reconstituted HDL agent CSL-111 was not associated with a reduction in atheroma volume compared with placebo. Treatment with CSL-111 was associated with a change in atheroma volume within the treatment arm from baseline to 6 week follow-up. ACC 2007